Steen Riisgaard

Steen Riisgaard currently works at Xellia Pharmaceuticals ApS, as Chairman, Villum Fonden, as Vice Chairman, New Xellia Group A, as Chairman, Novo Nordisk Fonden, as Director, and CAT Forsknings og Teknologipark A, as Director.
Mr. Riisgaard also formerly worked at Novozymes A, as President & Chief Executive Officer from 2000 to 2013, ROCKWOOL A, as Second Deputy Chairman in 2011, Egmont Fonden, as Chairman, ALK-Abello A, as Chairman from 2017 to 2020, Egmont International Holding A, as Chairman from 2014 to 2017, COWI A, as Chairman, World Wildlife Fund Denmark, as Chairman, Egmont Holding A, as Chairman-Supervisory Board, COWI Holding A, as Chairman from 2013 to 2021, Egmont (Denmark), as Chairman, Novo Holdings A, as Director from 2013 to 2018, the University of Aarhus, as Director, The European Association for Bioindustries, as Director, Novo Nordisk A, as Executive Vice President-Enzyme Business in 2000, Foss Electric Holding, as Research Microbiologist, Statens Serum Institute, as Principal, Corbion NV, as Independent Member-Supervisory Board from 2014 to 2026, and Novo Industri Japan Ltd., as Principal.
Mr. Riisgaard received his graduate degree in 1976 from the University of Copenhagen.